Newsroom

Congress should protect a program that helps provide medications to patients most in need.

Trump 340B order targets clinics serving the poor

President Donald Trump on Friday announced four executive orders to advance policies forcing community health centers that receive 340B drug discounts to cut patients' costs for Epi-Pens and insulin, tying Medicare payment for outpatient drugs to international prices, passing drugmaker rebates to patients and allowing personal drug importation.

Last week, I documented that nearly half of U.S. pharmacies now participate in the 340B Drug Pricing Program. Below, we update our exclusive analysis of the biggest specialty pharmacies within 340B.

A federal appeals court has ruled the Trump administration can install nearly 30% cuts to the 340B drug discount program.

A coalition of think tanks and health care organizations – dubbed Lower Drug Prices Now – just launched a campaign to promote price controls on coronavirus treatments in development. Several Democratic House leaders want such language included in future stimulus packages.

The COVID-19 crisis has been a brutal lesson on the limitations of government action and imagination. The response, thus far, has been a ‘business as usual’ expansion of entitlements and interventions in an attempt for the government (programs, loans, direct payments, welfare, food assistance, etc.) to take the place of private sector activity. It has not worked.

Patients across the country are receiving hospital care not knowing if they will get stuck with enormous and unexpected bills when they are released.